IFNA1 and renal cell carcinoma: We discounted this possibility for two reasons: (1) an IFN-signature is seen in early-stage RCC samples [31], but IFN is not usually administered to RCC patients with localized disease, and (2) the specimens in our studies were obtained immediately post-surgery, but IFN is typically administered only after surgical removal of the primary tumor.